TARA · Protara Therapeutics Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 2.41 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 38 / 14 / 20 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 3 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -19.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +68.1% |
| Market cap (USD) | $284.5M |